Graph AI, a U.S.-based healthcare tech startup focusing on drug safety, has raised $3 million in seed funding led by Bessemer Venture Partners. The startup develops AI models to automate detection and monitoring of adverse drug reactions, improving patient safety and regulatory reporting. The capital will go toward product development, data partnerships, and scaling its platform across global pharmaceutical clients. As regulatory scrutiny and compliance needs grow, Graph AI’s solution is positioned to support the AI-powered evolution of pharmacovigilance systems.